A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) acr 17 June 2024
An Expert View from Danie du Plessis, executive vice president, medical affairs at Kyowa Kirin, and chair of the Medical Affairs Professional Society (MAPS) boa 29 May 2024
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technolog 21 May 2024
In an Expert View column.Bruce Leuchter.chief executive of Neurvati Neurosciences.a Blackstone Life Sciences portfolio company.outlines the importance of increa 17 May 2024
A new age of innovation in immunology could change medical practice and people’s lives, as long as all parts of the system learn, evolve and work together, writ 1 May 2024
A second Expert View piece from Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at Pharm 4 April 2024
Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex, provides an Expert View. 29 February 2024
In an Expert View piece, Mark Seymour, Director and Head of Media at FleishmanHillard, argues that in the ever-evolving world of healthcare, the rules of commun 8 February 2024
An Expert View from Ross Maclean, Precision Health Economics, Outcomes Research and Head of Medical Affairs,Precision Value and Health, and the same company's J 5 February 2024
The life sciences landscape has adapted in tandem with data management solutions over the past several years.attracting significant investment.However. 3 January 2024
Erika Sloan from the global consulting firm CRA and Siddharth Arun discuss the future of innovation of CAR-T therapies in the solid tumor space and challenges t 15 December 2023
In 1984, Congress passed and the President signed into law the Drug Price Competition and Patent Term Restoration Act, better known as the Hatch-Waxman Act. 21 November 2023
The global pharmaceutical industry is going through a significant shift in the way it operates. Dr Stefanie Lietsch-Dallwig shares her insights on how this shif 20 October 2023
Patrick Branch, a Japan-based strategy consultant from LEK Consulting, provides an Expert View on the ‘new map’ for healthcare firms in Asia. 11 October 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.